Phase I/II Study of Umbralisib (TGR-1202), Ublituximab (TG-1101), and Pembrolizumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Richter’s Transformation: 5-Year Follow-up

Drug Category : Array
Conference Category : Array
Lead Author : Roeker L, et al.
Published Date : 18/09/2021
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2021/09/Roeker-iwCLL-2021-U2-Pembro-updated-9.19.21.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top